Cannabis Rescheduling Opens the Door to Federal Tax Relief and R&D Tax Credits
A recent shift in federal policy materially changes how certain cannabis businesses should evaluate their Research and Development (R&D) Tax Credit position. On April 22, 2026, the Drug Enforcement Administration (DEA) issued a final order rescheduling specific cannabis products from Schedule I to Schedule III under the Controlled Substances Act. This change applies primarily to…